By G HossainPosted on August 20, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos. Regeneron wins FDA approval to challenge Ipsen for rare bone disease market Post navigation Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decisionScribe’s early-stage IPO standout defies biotech’s derisking trend